Article
Gilead snaps ups German virology biotech MYR, nabbing a European-approved hepatitis D therapy
Rating:
0.0
Views:
81
Likes:
1
Library:
1
Gilead Sciences is all about cancer these days, right? Well, no: The speedy authorization of remdesivir in COVID-19 saw its infectious disease credentials reinstated this year, and, now, it's doubling down with a deal to buy out MYR Pharmaceuticals.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value